Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-25 @ 1:25 AM
Ignite Modification Date: 2025-12-25 @ 11:35 PM
NCT ID: NCT00418093
Description: None
Frequency Threshold: 5
Time Frame: None
Study: NCT00418093
Study Brief: Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Group 1 None None None 1 19 19 19 View
Serious Events(If Any):

Serious Events

Term Type Organ System Vocab View
Thrombosis/thrombus/embolism NON_SYSTEMATIC_ASSESSMENT Vascular disorders CTCAE v3 View
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Neutropenia NON_SYSTEMATIC_ASSESSMENT Blood and lymphatic system disorders CTCAE v3.0 View
Fatigue None General disorders CTCAE (3.0) View
Neuropathy None Nervous system disorders CTCAE (3.0) View
Nausea/Vomiting None Gastrointestinal disorders CTCAE (3.0) View
Hypertension None Cardiac disorders CTCAE (3.0) View
Allergic Reaction to Oxaliplatin None Immune system disorders CTCAE (3.0) View